Precision receives two notices of allowance from USPTO for PBGENE-HBV

Precision BioSciences (DTIL) announced that it has received two notices of allowance from the U.S. Patent and Trademark Office, or USPTO, for patent applications relating to the company’s PBGENE-HBV program. The ‘136 application includes composition of matter claims that, when granted, will encompass the Arcus nuclease utilized in PBGENE-HBV. The ‘982 application includes composition of matter claims that, when granted, will encompass any polypeptide-including the PBGENE-HBV Arcus nuclease-that comprises a novel, shortened polypeptide linker developed by Precision. Future Arcus nucleases incorporating this novel polypeptide linker will also be covered by the granted claims.